Paul Hastings LLP advised J.P. Morgan and Leerink Partners as co-lead placement agents, and Stifel co-placement agent, in the transaction. Lexeo Therapeutics, Inc. (Nasdaq: LXEO) has entered...
Lexeo Therapeutics’ $95 Million Private Placement
Humacyte’s $40 Million Public Offering
Covington & Burling represented Humacyte, while Paul Hastings advised TD Cowen, Cantor and BTIG in the offering. Humacyte, Inc. executed an underwritten public offering of 13,400,000 shares...
PepGen’s $80.1 Million Offering
Paul Hastings LLP advised Leerink Partners on the matter. PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the...
Skye Bioscience’s $50.25 Million Private Placement
Paul Hastings LLP advised the lead placement agent and the placement agent. Skye Bioscience, Inc. (OTCQB: SKYE), a clinical stage biotechnology company focused on the discovery,...
Esperion Therapeutics’ $85.1 Million Public Offering
Paul Hastings LLP advised Jefferies LLC as sole book running manager in connection with Esperion Therapeutics, Inc.’s offering. Esperion Therapeutics, Inc. announced the pricing of its...
Harpoon Therapeutics’ $150 Million Private Placement
Paul Hastings LLP advised TD Cowen and the placement agents in connection with Harpoon Therapeutics’ offering. Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T...
Lexeo Therapeutics’ $100 Million Initial Public Offering
Paul Hastings LLP advised the underwriters in connection with Lexeo Therapeutics’ IPO. Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to transforming...
CymaBay Therapeutics’ $258.75 Million Follow-On Offering
Cooley advised CymaBay, and Paul Hastings advised the representatives of the underwriters. CymaBay Therapeutics, Inc. announced its $258.75 million follow-on offering of common stock and pre-funded...
Seo Salimi joins Paul Hastings as Partner in Equity Capital Markets and Life Sciences practice
Paul Hastings LLP announced that experienced capital markets lawyer Seo Salimi has joined the firm in New York as a partner, co-head of the equity capital...
Seo Salimi Joins Paul Hastings as a Partner in New York
Paul Hastings LLP announced that experienced capital markets lawyer Seo Salimi has joined the firm in New York as a partner, co-head of the equity capital...
Coherus’ Acquisition of Surface Oncology
Arnold & Porter advised Coherus Biosciences Inc. on the deal, and Goodwin advised Surface Oncology. Coherus Biosciences Inc. (Coherus) announced its acquisition of Surface Oncology Inc. (Surface),...
HOOKIPA Pharma’s $50 Million Public Offering of Common Stock and Convertible Preferred Stock
Goodwin Procter advised HOOKIPA, and Duane Morris advised the underwriters involved in the offering. HOOKIPA Pharma Inc. (Nasdaq: HOOK) announced its underwritten public offering of 22,900,768...